Teleflex Incorporated announced that Jason Weidman will become the company’s President and Chief Executive Officer, effective June 8, 2026. Weidman will also join the board of directors. The appointment follows the interim leadership of Stuart Randle, who has served as President and CEO since January 2026.
Weidman brings more than 25 years of experience in the medical‑technology industry, most recently serving in senior leadership roles at Medtronic plc. His track record of scaling high‑growth medical‑device businesses and driving operational efficiency positions him to accelerate Teleflex’s transformation agenda.
Teleflex’s transformation strategy has focused on consolidating its vascular, interventional, and surgical businesses while divesting non‑core units. The company completed the sale of its acute care, interventional urology, and OEM businesses for $2.03 billion, a portion of which will fund a $1 billion share‑buyback and $800 million debt reduction. In February 2025, Teleflex announced the acquisition of Biotronik’s Vascular Intervention business for €760 million, which closed on July 1, 2025. The acquisition is expected to strengthen Teleflex’s presence in the cath lab and expand its product portfolio.
Teleflex reported a Q4 2025 adjusted earnings per share of $1.93, missing analyst expectations of $3.74 by $1.81 and falling 49 % below consensus. Revenue for the quarter was $568.98 million, a 38 % miss against the $925.44 million forecast. The miss was driven by a 28.5 % decline in total revenue, largely due to weaker demand in legacy product lines and the impact of tariffs on imported components. Adjusted gross margin contracted by 200 basis points in 2025, reflecting higher logistics and distribution costs and tariff exposure. Management has guided for 2026 adjusted EPS of $6.25–$6.55, below the February 2026 consensus of $6.77, signaling caution amid ongoing margin compression.
Analysts have adjusted ratings in response to the earnings miss and guidance. Some have downgraded the stock to “sell” while others have maintained a “hold” or “outperform” stance, reflecting divergent views on Teleflex’s ability to navigate the integration of the Biotronik acquisition and the impact of tariff‑related cost pressures.
Dr. Stephen Klasko, Teleflex’s Chairman of the Board, said, “We're thrilled to welcome Jason to Teleflex. Following the completion of the divestitures, Teleflex will be a fundamentally transformed company, with a portfolio focused on our core interventional, critical care and high acuity hospital markets. Jason's medical technology expertise is closely aligned with our focused product portfolio, and his track record of driving growth, advancing product innovations and expanding global markets make him an ideal candidate to lead Teleflex's go-forward strategy.” Weidman added, “It's an honor for me to join Teleflex at such an important inflection point and to help lead the Company into its next phase of growth. Having spent my entire career in the medical technology industry, I see a clear opportunity for Teleflex to build on its strong foundation and commitment to innovation, further shaping the future of healthcare while advancing our purpose of improving the health and quality of people's lives.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.